DNA Bridges, Inc. Corporate Logo Bridging Science and Products Industry and Client News on Twitter Like Us on Facebook Business Intelligence on LinkedIn

We understand toay's complex markets.

December 10, 2009
Azaya Therapeutics Receives FDA Authorization to Start Phase I Cancer Trial

November 11-13, 2009
Texas Life Science Conference 2009
The Brown Foundation Institute of Molecular Medicine
Houston, Texas

November 2-4, 2009
BIO-Europe 2009
Messe Wien Exhibition & Congress Center
Vienna, Austria

October 12-16, 2009
BioProcess International Conference and Exhibition
Raleigh Convention Center
Raleigh-Durham, North Carolina

October 5, 2009
Depomed, Inc. Announces Positive Top-Line Results from Phase 3 Clinical Trial of DM-1796 in Postherpetic Neuralgia
Menlo Park, Calif

September 22, 2009
Selexis and Neogenix Oncology enter into research services agreement
Geneva, Switzerland, and Great Neck, New York

September 18, 2009
Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances
Collegeville, PA and San Diego, CA

September 17, 2009
to-BBB technology will be used by MedImmune to evaluate brain drug delivery mechanism
Leiden, The Netherlands

August 31, 2009
Selexis and NKT Therapeutics enter into research services agreement
Geneva, Switzerland

August 10, 2009
Depomed Reports Encouraging Results of its Phase I Trial for DM-1992 Program in Parkinson's Disease
Menlo Park, Calif

August 6, 2009
to-BBB climbs up the international CNS drug delivery ranking
Leiden, The Netherlands

May 19, 2009
Personalized Medicine Can Increase Revenues

By Cammie Edwards, Ph.D., DNA Bridges, Inc.
Featured in Bio Show Daily, Tuesday, May 19, 2009. Page 33.

May 19, 2009
Cell Therapy is Alive and Well

By Cori Gorman, Ph.D., MBA, DNA Bridges, Inc.
Featured in Bio Show Daily, Tuesday, May 19, 2009. Page 22

May 12, 2009
U.S. Army funds TNO, and to-BBB to investigate protecting soldier’s brains from nerve agents

May 8, 2009
Annual Sigma Xi Meeting
Lecture: The Thrill of Victory the Agony of Defeat, the Trials of Developing a New Class of Therapeutics: From Gene to Cell Therapy, A Case Study

May 5, 2009
Viroblock SA Reports a 99% Boost of Efficacy of Facemasks against H5N1

April 14, 2009
Promising Test for Dendreon's Prostate Cancer Drug

April 11, 2009
FDA Approves Treatment of Head Lice - Target Health Was THE CRO

April 7, 2009
Dr. Cori Gorman Completes ISS Certification in Corporate Directors Enterprise 2009 Program

April 7, 2009
Editorial: Enabling High Throughput Drug Development

April 2, 2009
Editorial: Personalized Medicine Can Increase Revenues

March 31, 2009
Selexis launches Biosimilar Cell Line Development Program

March 31, 2009
Positive Results of Preclinical Studies in Antiviral Nasal Spray

March 24, 2009
Editorial: Cell Therapy Market
Cori Gorman, PhD, MBA



DNA Bridges Articles

Calendar of Events

  2014  |  2013  |  2012
  2011  |  2010  |  2009  |  2008
  2007  |  2006  |  2005  |  2004
  2003  |  2002  |  2001  |  2000